- Medical Oncologist & Internal Medicine, FRCP(C)
- Associate Professor, Oncology, University of Western Ontario
- Interim Medical Director, Systemic Therapy Program, Verspeeten Family Cancer Centre
- Interim Head, division of Medical Oncology, Department of Oncology, UWO
- Local Chair of the Medical Oncology Associates
- Executive of MOA Ontario
Education
Dr. Vandenberg obtained his MD from the University of Ottawa and did a rotating internship at the University of Alberta. He commenced his Internal Medicine and Medical Oncology Residencies at the University of Ottawa and a one-year fellowship with the National Cancer Institute of Canada Clinical Trials Group at Queen’s University. He has a specialist certificate in Internal Medicine and has additional speciality training in Medical Oncology under the Royal College of Physicians and Surgeons of Canada. He is certified by the American Board of Internal Medicine in Medical Oncology.
Current practice
Dr. Vandenberg has served as medical director of the medical oncology program at St. Joseph’s Health Centre until this was amalgamated with the Oncology Program at the London Regional Cancer Centre in 1999. He has served as Acting head of Medical Oncology from 2000-2001. He was also Chair of the Breast Cancer Multi-disciplinary Team from 1997-2003. He is currently Verspeeten Family Cancer Centre Site Representative for the National Cancer Institute of Canada Clinical Trials Group and is a member of the Board of the Ontario Medical Oncology Associates.
Research interests
Dr. Vandenberg’s research interests include evaluating new treatments for metastatic breast cancer, the treatment of bone metastases, phase II and III trials in breast cancer, neuro imagining studies of “chemo brain”, tumour markers and third world cancer care.
Selected Publications
- Vandenberg T, Bramwell V. Caution with breast-conserving surgery. Letter. Can Med Assoc J 167:1099, 2002.
- Gelmon K, Vandenberg T, Panasci L, Norris B, Crump M, Douglas L, Walsh W, Matthews S, Seymour L. A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group trial, IND.129. Ann Oncol 14: 543-8, 2003.
- Younus J, Vandenberg T. A practical overview of aromatase inhibitors. Aniticancer Res 25: 2497-2502, 2005.
- Bramwell VHC, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Perera F, Vandenberg TA, Chambers AF. Osteopontin in metastatic breast cancer: serial plasma measurement predicts clinical outcome. Accepted for publication, Clinical Cancer Research, 2006.
- Contribution of osteopontin to the development of bone metastasis. Allan AL, Tuck AB, Bramwell VHC, Vandenberg TA, Winquist EW, Chambers AF. In: Singh G and Rabbani SA eds. Bone Metastasis: Experimental and Clinical Therapeutics. Totowa, NJ: Humana, 2005: 107-124.
